PMID- 28472071
OWN - NLM
STAT- MEDLINE
DCOM- 20170915
LR  - 20181113
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 12
IP  - 5
DP  - 2017
TI  - Associations between MRI features versus knee pain severity and progression: Data 
      from the Vancouver Longitudinal Study of Early Knee Osteoarthritis.
PG  - e0176833
LID - 10.1371/journal.pone.0176833 [doi]
LID - e0176833
AB  - OBJECTIVE: To determine associations between features of osteoarthritis (OA) on 
      MRI and knee pain severity and knee pain progression. DESIGN: Baseline, 3.3- and 
      7.5-year assessments were performed for 122 subjects with baseline knee pain (age 
      40-79), sample-weighted for population (with knee pain) representativeness. MRIs 
      were scored for: osteophytes (0:absent to 3:large); cartilage (0:normal to 4:full 
      thickness defect; 0/1 collapsed); subchondral sclerosis (0:none to 3:>50% of 
      site), subchondral cyst (0:absent to 3:severe), bone marrow lesions (0:none to 
      3:>/=50% of site); and meniscus (0:normal to 3:maceration/resection), in 6-8 
      regions each. Per feature, scores were averaged across regions. 
      Effusion/synovitis (0:absent to 3:severe) was analyzed as >/=2 vs. <2. Linear 
      models predicted WOMAC knee pain severity (0-100), and binary models predicted 
      10+ (minimum perceptible clinical improvement [MPCI]) and 20+ (minimum clinically 
      important difference [MCID]) increases. Models were adjusted for age, sex, BMI 
      (and follow-up time for longitudinal models). RESULTS: Pain severity was 
      associated with osteophytes (7.17 per unit average; 95% CI = 3.19, 11.15) and 
      subchondral sclerosis (11.03; 0.68, 21.39). MPCI-based pain increase was 
      associated with osteophytes (odds ratio per unit average 3.20; 1.36, 7.55), 
      subchondral sclerosis (5.69; 1.06, 30.44), meniscal damage (1.68; 1.08, 2.61) and 
      effusion/synovitis >/=2 (2.25; 1.07, 4.71). MCID-based pain increase was associated 
      with osteophytes (3.79; 1.41, 10.20) and cartilage defects (2.42; 1.24, 4.74). 
      CONCLUSIONS: Of the features investigated, only osteophytes were consistently 
      associated with pain cross-sectionally and longitudinally in all models. This 
      suggests an important role of bone in early knee osteoarthritis.
FAU - Sayre, Eric C
AU  - Sayre EC
AD  - Arthritis Research Canada, Richmond, BC, Canada.
FAU - Guermazi, Ali
AU  - Guermazi A
AD  - Radiology, Boston University School of Medicine, Boston, MA, United States of 
      America.
FAU - Esdaile, John M
AU  - Esdaile JM
AD  - Arthritis Research Canada, Richmond, BC, Canada.
AD  - Medicine, University of British Columbia, Vancouver, BC, Canada.
AD  - Medicine, University of Calgary, Calgary, AB, Canada.
AD  - School of Medicine, University of Queensland, Brisbane St. Lucia, QLD, Australia.
FAU - Kopec, Jacek A
AU  - Kopec JA
AD  - Arthritis Research Canada, Richmond, BC, Canada.
AD  - School of Population & Public Health, University of British Columbia, Vancouver, 
      BC, Canada.
FAU - Singer, Joel
AU  - Singer J
AD  - School of Population & Public Health, University of British Columbia, Vancouver, 
      BC, Canada.
FAU - Thorne, Anona
AU  - Thorne A
AD  - School of Population & Public Health, University of British Columbia, Vancouver, 
      BC, Canada.
FAU - Nicolaou, Savvas
AU  - Nicolaou S
AD  - Radiology, University of British Columbia, Vancouver, BC, Canada.
FAU - Cibere, Jolanda
AU  - Cibere J
AD  - Arthritis Research Canada, Richmond, BC, Canada.
AD  - Medicine, University of British Columbia, Vancouver, BC, Canada.
LA  - eng
PT  - Journal Article
DEP - 20170504
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Aged
MH  - Female
MH  - Humans
MH  - Longitudinal Studies
MH  - Male
MH  - Middle Aged
MH  - Osteoarthritis, Knee/complications/*diagnostic imaging
MH  - Pain/*etiology
MH  - *Pain Measurement
PMC - PMC5417516
COIS- Competing Interests: Ali Guermazi is President of Boston Imaging Core Lab, LLC, 
      and consultant to AstraZeneca, TissueGene, OrthoTrophix, Merck Serono and 
      Genzyme. No other authors have competing interests to declare. This does not 
      alter our adherence to PLOS ONE policies on sharing data and materials.
EDAT- 2017/05/05 06:00
MHDA- 2017/09/16 06:00
PMCR- 2017/05/04
CRDT- 2017/05/05 06:00
PHST- 2016/11/15 00:00 [received]
PHST- 2017/04/18 00:00 [accepted]
PHST- 2017/05/05 06:00 [entrez]
PHST- 2017/05/05 06:00 [pubmed]
PHST- 2017/09/16 06:00 [medline]
PHST- 2017/05/04 00:00 [pmc-release]
AID - PONE-D-16-45427 [pii]
AID - 10.1371/journal.pone.0176833 [doi]
PST - epublish
SO  - PLoS One. 2017 May 4;12(5):e0176833. doi: 10.1371/journal.pone.0176833. 
      eCollection 2017.